<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04817813</url>
  </required_header>
  <id_info>
    <org_study_id>PI20/596</org_study_id>
    <nct_id>NCT04817813</nct_id>
  </id_info>
  <brief_title>Long-term Outcomes After Breast Cancer Liver Metastasis Surgery: an European, Retrospective, Snapshot Study</brief_title>
  <acronym>LIBREAST</acronym>
  <official_title>LIBREAST STUDY: Long-term Outcomes After Breast Cancer Liver Metastasis Surgery: an European, Retrospective, Snapshot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Miguel Servet</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Asociación Española de Cirujanos</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Miguel Servet</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Breast cancer ranks as the top leading malignant tumors among females, and also accounts for&#xD;
      the most common cause of tumor related mortality in females worldwide. Approximately, 20-30%&#xD;
      of breast cancer cases develop metastasis, while 50% of patients will suffer from breast&#xD;
      cancer liver metastasis. The proper indication for surgical treatment of breast cancer liver&#xD;
      metastasis is still a matter of discussion. Surgery is becoming more practical and effective&#xD;
      than conservative treatment in improving the outcomes of patients with breast cancer liver&#xD;
      metastasis and liver metastasis surgery is included in an onco- surgical strategy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Breast cancer ranks as the top leading malignant tumors among females, and also accounts for&#xD;
      the most common cause of tumor related mortality in female's worldwide . Approximately,&#xD;
      20-30% of breast cancer (BC) cases develop metastasis, while 50% of patients will suffer from&#xD;
      breast cancer liver metastases (BCLM) . The presence of liver metastasis has markedly&#xD;
      worsened the prognosis of patients, and the median survival was reported to be 3.8-29 months.&#xD;
&#xD;
      Metastatic breast cancer is considered to be a disseminated disease and many oncologists&#xD;
      remain reluctant to include surgery within the multimodal treatment strategy of these&#xD;
      patients . Although systemic treatments can achieve approximately 60% of responses in breast&#xD;
      cancer recurrence, long-term survival is exceptional only with medical treatment . Without&#xD;
      liver resection, the average survival reported after the first onset of liver metastases is&#xD;
      distributed over a range from 1 to 15 months. Surgery is becoming more functional and&#xD;
      effective than conservative treatment in improving the poor outcomes of patients with BCLM .&#xD;
      However, there is no generally acknowledged set of standards for identifying candidates who&#xD;
      will benefit from surgery. The proper indication for surgical treatment is still a matter of&#xD;
      discussion; surgical resection should be assessed when the following premises are met: low&#xD;
      surgical risk, low metastasis number, complete macroscopic liver removal, absence of proven&#xD;
      extrahepatic disease by positron emission tomography and computed tomography, objective&#xD;
      response to chemotherapy before surgery, and long disease-free interval. Breast cancer liver&#xD;
      metastasis surgery (BCLMS) is included in an onco-surgical strategy.&#xD;
&#xD;
      Most of the published series of patients with liver metastases of breast cancer who have&#xD;
      undergone surgery come from a single center or few centers and there are hardly any long-term&#xD;
      results, so we consider necessary to carry out a multicenter review of patients who underwent&#xD;
      surgery in high volume centers across Europe belonging to the European-African&#xD;
      Hepato-Pancreato-Biliary Association (E-AHPBA) to asses survival and disease-free survival&#xD;
      and to determine which patients may benefit from surgery.&#xD;
&#xD;
      This retrospective multicenter cohort study in centers performing BCLMS aims to provide an&#xD;
      assessment of the outcomes across E-AHPBA centers.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 15, 2021</start_date>
  <completion_date type="Anticipated">July 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 15, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Survival and disease-free survival at 1st year.</measure>
    <time_frame>1 year.</time_frame>
    <description>Disease-free time and survival at 1st year.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Survival and disease-free survival at 3th year.</measure>
    <time_frame>3 years.</time_frame>
    <description>Disease-free time and survival at 3th year.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Survival and disease-free survival at 5th year.</measure>
    <time_frame>5 years.</time_frame>
    <description>Disease-free time and survival at 5th year.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Preoperative details-Tumor TNM</measure>
    <time_frame>5 years.</time_frame>
    <description>Stage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preoperative details- Dysplasia grade</measure>
    <time_frame>5 years.</time_frame>
    <description>Low-Moderate- High</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preoperative details- Tumor subtypes</measure>
    <time_frame>5 years.</time_frame>
    <description>Yes/No of Luminal A/Luminal B/ HER2+/Triple negative-basal like</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preoperative details- Location of breast cancer</measure>
    <time_frame>5 years.</time_frame>
    <description>Breast Quadrant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preoperative details- Segment location</measure>
    <time_frame>5 years.</time_frame>
    <description>Segment 1 to 8</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preoperative details- Number of liver metastasis</measure>
    <time_frame>5 years.</time_frame>
    <description>Number</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intra-operative events</measure>
    <time_frame>Surgery date.</time_frame>
    <description>Satava's Classification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nº metastasis intraoperatively</measure>
    <time_frame>Surgery date.</time_frame>
    <description>Number</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-operative curse- Re-hospitalization cause</measure>
    <time_frame>30 days.</time_frame>
    <description>Cause of re-hospitalization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-operative curse- Complications</measure>
    <time_frame>30 days.</time_frame>
    <description>Clavien- Dindo Classification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-operative curse- ICU admission length of stay</measure>
    <time_frame>30 days.</time_frame>
    <description>Days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Histopathological details- Ki67</measure>
    <time_frame>30 days.</time_frame>
    <description>Percent</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Histopathological details- Resection status</measure>
    <time_frame>30 days.</time_frame>
    <description>R0-R1-R2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Histopathological details- Nº of lesions</measure>
    <time_frame>30 days.</time_frame>
    <description>Number</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Follow up- Adjuvant systemic treatment</measure>
    <time_frame>5 years.</time_frame>
    <description>Yes/No of Chemotherapy, Hormonetherapy, AntiHER2Therapy, Antiangiogenics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Follow up- Liver metastasis relapse</measure>
    <time_frame>5 years.</time_frame>
    <description>Location of relapse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Follow up- Date of death</measure>
    <time_frame>5 years.</time_frame>
    <description>Date</description>
  </secondary_outcome>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Liver Metastases</condition>
  <condition>Surgery</condition>
  <eligibility>
    <study_pop>
      <textblock>
        All patients operated on in the participating European centers with breast cancer liver&#xD;
        metastases during the study period (between January 1st 2010 and December 31st 2015) and&#xD;
        that meet the inclusion criteria.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients ≥ 18 year old.&#xD;
&#xD;
          -  Scheduled surgery for breast cancer liver metastases between January 1st 2010 and&#xD;
             December 31st 2015&#xD;
&#xD;
          -  American Society of Anesthesiologists (ASA) score I-III.&#xD;
&#xD;
          -  They have signed the informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients under 18 year old.&#xD;
&#xD;
          -  ASA ≥ IV.&#xD;
&#xD;
          -  Urgent surgery.&#xD;
&#xD;
          -  Patients who have not signed the informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mario Serradilla Martín, MD FACS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zaragoza, Spain. Miguel Servet University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mario Serradilla Martín</name>
      <address>
        <city>Zaragoza</city>
        <zip>50008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Mario Serradilla Martín, MD FACS</last_name>
      <phone_ext>144332</phone_ext>
      <email>marioserradilla@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <results_reference>
    <citation>He X, Zhang Q, Feng Y, Li Z, Pan Q, Zhao Y, Zhu W, Zhang N, Zhou J, Wang L, Wang M, Liu Z, Zhu H, Shao Z, Wang L. Resection of liver metastases from breast cancer: a multicentre analysis. Clin Transl Oncol. 2020 Apr;22(4):512-521. doi: 10.1007/s12094-019-02155-2. Epub 2019 Jun 22.</citation>
    <PMID>31230220</PMID>
  </results_reference>
  <results_reference>
    <citation>Chen QF, Huang T, Shen L, Wu P, Huang ZL, Li W. Prognostic factors and survival according to tumor subtype in newly diagnosed breast cancer with liver metastases: A competing risk analysis. Mol Clin Oncol. 2019 Sep;11(3):259-269. doi: 10.3892/mco.2019.1890. Epub 2019 Jul 1.</citation>
    <PMID>31396386</PMID>
  </results_reference>
  <results_reference>
    <citation>Sadot E, Lee SY, Sofocleous CT, Solomon SB, Gönen M, Kingham TP, Allen PJ, DeMatteo RP, Jarnagin WR, Hudis CA, D'Angelica MI. Hepatic Resection or Ablation for Isolated Breast Cancer Liver Metastasis: A Case-control Study With Comparison to Medically Treated Patients. Ann Surg. 2016 Jul;264(1):147-154. doi: 10.1097/SLA.0000000000001371.</citation>
    <PMID>26445472</PMID>
  </results_reference>
  <results_reference>
    <citation>Margonis GA, Buettner S, Sasaki K, Kim Y, Ratti F, Russolillo N, Ferrero A, Berger N, Gamblin TC, Poultsides G, Tran T, Postlewait LM, Maithel S, Michaels AD, Bauer TW, Marques H, Barroso E, Aldrighetti L, Pawlik TM. The role of liver-directed surgery in patients with hepatic metastasis from primary breast cancer: a multi-institutional analysis. HPB (Oxford). 2016 Aug;18(8):700-5. doi: 10.1016/j.hpb.2016.05.014. Epub 2016 Jun 29.</citation>
    <PMID>27485066</PMID>
  </results_reference>
  <results_reference>
    <citation>Treska V, Cerna M, Kydlicek T, Treskova I. Prognostic factors of breast cancer liver metastasis surgery. Arch Med Sci. 2015 Jun 19;11(3):683-5. doi: 10.5114/aoms.2015.52376.</citation>
    <PMID>26170865</PMID>
  </results_reference>
  <results_reference>
    <citation>Díaz R, Santaballa A, Munárriz B, Calderero V. Hepatic resection in breast cancer metastases: should it be considered standard treatment? Breast. 2004 Jun;13(3):254-8. Review.</citation>
    <PMID>15177433</PMID>
  </results_reference>
  <results_reference>
    <citation>Ramia JM, Villar J, Villegas T, Muffak K, Garrote D, Ferrón JA. [Surgical treatment of liver metastases from breast cancer]. Cir Esp. 2005 Nov;78(5):318-22. Spanish.</citation>
    <PMID>16420849</PMID>
  </results_reference>
  <results_reference>
    <citation>Figueras J, González HD. [Surgical treatment of breast cancer liver metastasis. The great assignment awaiting Spanish hepatic surgery]. Cir Esp. 2008 Nov;84(5):239-40. Spanish.</citation>
    <PMID>19080906</PMID>
  </results_reference>
  <results_reference>
    <citation>Roffman CE, Buchanan J, Allison GT. Charlson Comorbidities Index. J Physiother. 2016 Jul;62(3):171. doi: 10.1016/j.jphys.2016.05.008. Epub 2016 Jun 11.</citation>
    <PMID>27298055</PMID>
  </results_reference>
  <results_reference>
    <citation>Satava RM. Identification and reduction of surgical error using simulation. Minim Invasive Ther Allied Technol. 2005;14(4):257-61.</citation>
    <PMID>16754172</PMID>
  </results_reference>
  <results_reference>
    <citation>Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004 Aug;240(2):205-13.</citation>
    <PMID>15273542</PMID>
  </results_reference>
  <results_reference>
    <citation>The Royal College of Pathologists. Standards and Minimum Datasets for Reporting Cancers Minimum dataset for the histopathological reporting of pancreatic, ampulla of Vater and bile duct carcinoma. London R Coll Pathol. 2002.</citation>
  </results_reference>
  <results_reference>
    <citation>Rahbari NN, Garden OJ, Padbury R, Maddern G, Koch M, Hugh TJ, Fan ST, Nimura Y, Figueras J, Vauthey JN, Rees M, Adam R, Dematteo RP, Greig P, Usatoff V, Banting S, Nagino M, Capussotti L, Yokoyama Y, Brooke-Smith M, Crawford M, Christophi C, Makuuchi M, Büchler MW, Weitz J. Post-hepatectomy haemorrhage: a definition and grading by the International Study Group of Liver Surgery (ISGLS). HPB (Oxford). 2011 Aug;13(8):528-35. doi: 10.1111/j.1477-2574.2011.00319.x. Epub 2011 Jun 7. Review.</citation>
    <PMID>21762295</PMID>
  </results_reference>
  <results_reference>
    <citation>Brooke-Smith M, Figueras J, Ullah S, Rees M, Vauthey JN, Hugh TJ, Garden OJ, Fan ST, Crawford M, Makuuchi M, Yokoyama Y, Büchler M, Weitz J, Padbury R. Prospective evaluation of the International Study Group for Liver Surgery definition of bile leak after a liver resection and the role of routine operative drainage: an international multicentre study. HPB (Oxford). 2015 Jan;17(1):46-51. doi: 10.1111/hpb.12322. Epub 2014 Jul 24.</citation>
    <PMID>25059275</PMID>
  </results_reference>
  <results_reference>
    <citation>Rahbari NN, Garden OJ, Padbury R, Brooke-Smith M, Crawford M, Adam R, Koch M, Makuuchi M, Dematteo RP, Christophi C, Banting S, Usatoff V, Nagino M, Maddern G, Hugh TJ, Vauthey JN, Greig P, Rees M, Yokoyama Y, Fan ST, Nimura Y, Figueras J, Capussotti L, Büchler MW, Weitz J. Posthepatectomy liver failure: a definition and grading by the International Study Group of Liver Surgery (ISGLS). Surgery. 2011 May;149(5):713-24. doi: 10.1016/j.surg.2010.10.001. Epub 2011 Jan 14.</citation>
    <PMID>21236455</PMID>
  </results_reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>February 5, 2021</study_first_submitted>
  <study_first_submitted_qc>March 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 26, 2021</study_first_posted>
  <last_update_submitted>March 23, 2021</last_update_submitted>
  <last_update_submitted_qc>March 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Miguel Servet</investigator_affiliation>
    <investigator_full_name>Mario Serradilla, MD, FACS</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Breast cancer</keyword>
  <keyword>Liver metastases</keyword>
  <keyword>Hepatic surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

